Help us: Donate
Follow us on:
×

MMTP Finally Gets Government Approval

It has been quite a while since the community had fundraised for the MMTP senolytics project; unfortunately, the start of the experiment was delayed due to a number of issues encountered along the way. However, today, we are delighted to announce that the experiment has been approved and has finally launched!

The COVID-19 situation

To really top this off and add some extra problems, the study was just about ready to launch when COVID-19 made an appearance. Labs were closing down and supplies and deliveries were erratic, but I managed to get everything together and got ready to begin, thanks to all the people and scientists that are still working to make science happen.

Experiment details

A total of 40 C57BL mice will be treated with a combination of senolytics (ABT-263, ABT-199, dasatinib, isoquercetin) and compared to 40 control mice. The mice were all 18 months old when the experiment started. Blood samples have been taken to determine aging marker analyses before the start of the senolytic treatment, and subsequent blood draws will happen during the study to track changes and determine the health of the animals in addition to a range of other murine health parameters.



Stay tuned for more news!

About the author
Alexandra Stolzing

Alexandra Stolzing

Alexandra has dedicated her scientific career to the understanding and development of rejuvenation biology. She holds a PhD from Humboldt University Berlin for her work on degradation of damaged proteins by aged microglia, and received her Habilitierung (Professorial Qualification) at the University of Leipzig, Germany for her thesis “Modification of aging in mesenchymal stem cells” She worked at the Kroto Research Institute (UK) and as Group leader and deputy Head of Department at the Fraunhofer Institute for Cell Therapy and Immunology (Germany). She was tenured in 2018 as a full Professor for Biogerontological Engineering at Loughborough University, UK. In addition she has worked as VP for Research and CSO in start-up companies in the rejuvenation biology sector. She has over 70 academic publications and has led several international research consortia. Her research in aging spans areas including regenerative medicine, cell & gene therapy development and neurodegenerative diseases.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.